$CARM
Carisma Therapeutics Inc

2018 Q3 Form 10-Q Financial Statement

#000148500318000109 Filed on August 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.830M $2.350M $2.240M
YoY Change 134.97% 4.91% -35.45%
% of Gross Profit
Research & Development $3.372M $2.779M $2.909M
YoY Change -6.83% -4.47% -11.8%
% of Gross Profit
Depreciation & Amortization $60.00K $50.00K $90.00K
YoY Change 20.0% -44.44% 125.0%
% of Gross Profit
Operating Expenses $14.40M $9.030M $7.350M
YoY Change 57.34% 22.86% 8.58%
Operating Profit -$14.40M -$9.030M -$7.350M
YoY Change 57.34% 22.86% 13.22%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $382.0K $72.00K $34.00K
YoY Change 748.89% 111.76% 3300.0%
Pretax Income -$14.02M -$8.960M -$7.320M
YoY Change 53.9% 22.4% 12.79%
Income Tax
% Of Pretax Income
Net Earnings -$14.02M -$8.958M -$7.316M
YoY Change 53.93% 22.44% 12.71%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$182.0K -$158.8K -$296.5K
COMMON SHARES
Basic Shares Outstanding 77.01M shares 48.39M shares 24.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $57.90M $63.00M $15.80M
YoY Change 412.39% 298.73% 85.88%
Cash & Equivalents $57.86M $62.96M $15.75M
Short-Term Investments
Other Short-Term Assets $1.500M $800.0K $700.0K
YoY Change 87.5% 14.29% 75.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $59.39M $63.77M $16.46M
YoY Change 390.46% 287.45% 86.3%
LONG-TERM ASSETS
Property, Plant & Equipment $365.0K $421.0K $632.0K
YoY Change -37.61% -33.39% 101.27%
Goodwill $13.06M $13.06M $17.37M
YoY Change 0.0% -24.79%
Intangibles $46.40M $46.40M $60.50M
YoY Change 0.0% -23.31%
Long-Term Investments
YoY Change
Other Assets $61.00K $41.00K $77.00K
YoY Change -39.6% -46.75%
Total Long-Term Assets $59.91M $59.95M $78.59M
YoY Change -0.42% -23.72% 18050.12%
TOTAL ASSETS
Total Short-Term Assets $59.39M $63.77M $16.46M
Total Long-Term Assets $59.91M $59.95M $78.59M
Total Assets $119.3M $123.7M $95.05M
YoY Change 65.07% 30.16% 925.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.391M $1.310M $1.245M
YoY Change 1.83% 5.22% -32.88%
Accrued Expenses $5.170M $3.223M $2.492M
YoY Change 77.36% 29.33% 116.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.561M $4.533M $3.855M
YoY Change 48.98% 17.59% 28.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $311.0K $288.0K $148.0K
YoY Change 82.94% 94.59% 102.74%
Total Long-Term Liabilities $311.0K $288.0K $148.0K
YoY Change 82.94% 94.59% 102.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.561M $4.533M $3.855M
Total Long-Term Liabilities $311.0K $288.0K $148.0K
Total Liabilities $6.872M $4.821M $4.003M
YoY Change 50.24% 20.43% 29.93%
SHAREHOLDERS EQUITY
Retained Earnings -$179.3M -$165.3M -$136.7M
YoY Change 22.98% 20.94% -1.86%
Common Stock $77.00K $77.00K $25.00K
YoY Change 208.0% 208.0% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.40M $64.06M $25.91M
YoY Change
Total Liabilities & Shareholders Equity $119.3M $123.7M $95.05M
YoY Change 65.07% 30.16% 925.66%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$14.02M -$8.958M -$7.316M
YoY Change 53.93% 22.44% 12.71%
Depreciation, Depletion And Amortization $60.00K $50.00K $90.00K
YoY Change 20.0% -44.44% 125.0%
Cash From Operating Activities -$5.200M -$5.600M -$4.510M
YoY Change 17.38% 24.17% -9.98%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 90.00K 48.88M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.200M -5.600M -4.510M
Cash From Investing Activities 0.000 0.000 -10.00K
Cash From Financing Activities 90.00K 48.88M 0.000
Net Change In Cash -5.110M 43.28M -4.520M
YoY Change 15.61% -1057.52% -8.5%
FREE CASH FLOW
Cash From Operating Activities -$5.200M -$5.600M -$4.510M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5000 USD
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24685000 shares
us-gaap Depreciation And Amortization
DepreciationAndAmortization
101000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
10000 USD
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34702565 shares
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77010999 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
Sesen Bio, Inc.
dei Trading Symbol
TradingSymbol
SESN
CY2018Q2 ebio Working Capital Net
WorkingCapitalNet
59200000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
907000 USD
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1310000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3813000 USD
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3223000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
463000 USD
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
209000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
170330000 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
229239000 USD
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2905336 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2905336 shares
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13335458 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13335458 shares
CY2017Q4 us-gaap Assets
Assets
75097000 USD
CY2018Q2 us-gaap Assets
Assets
123713000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
14981000 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
63767000 USD
CY2017Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2200000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3700000 USD
CY2018Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3900000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2700000 USD
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
39600000 USD
CY2018Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
42300000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14680000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62961000 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25352000 USD
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15761000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14690000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62981000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9591000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
48291000 USD
CY2018Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8300000 shares
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
35000 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
77000 USD
CY2017Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
2581000 USD
CY2018Q2 us-gaap Construction Payable Current
ConstructionPayableCurrent
2274000 USD
CY2018Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0 USD
CY2018Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12528000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
174000 USD
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0 USD
CY2017Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12528000 USD
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77010999 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34702565 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77010999 shares
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
735000 USD
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
658000 USD
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2700000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
79000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2241000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4454000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2351000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4303000 USD
CY2017Q4 us-gaap Goodwill
Goodwill
13064000 USD
CY2018Q2 us-gaap Goodwill
Goodwill
13064000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-422000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
403000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
359000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-517000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-425000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
4000 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
200000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
426000 USD
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46400000 USD
CY2018Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46400000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75097000 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123713000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4720000 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4533000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58265000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
69000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9705000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9979000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-7316000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13377000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-8958000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12921000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
34000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
135000 USD
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
72000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
116000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
7350000 USD
us-gaap Operating Expenses
OperatingExpenses
13937000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
9030000 USD
us-gaap Operating Expenses
OperatingExpenses
13037000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7350000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13512000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9030000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13037000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
34000 USD
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
82000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
120000 USD
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41000 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
215000 USD
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
288000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
135000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
116000 USD
us-gaap Payments For Restructuring
PaymentsForRestructuring
104000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
301000 USD
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
806000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
58226000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
69000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
5000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40000 USD
CY2018Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6900000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
522000 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
421000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2909000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5783000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2779000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6034000 USD
CY2017Q4 us-gaap Restricted Cash
RestrictedCash
10000 USD
CY2018Q2 us-gaap Restricted Cash
RestrictedCash
20000 USD
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
20000 USD
CY2017Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
100000 USD
CY2017Q4 us-gaap Restructuring Reserve
RestructuringReserve
111000 USD
CY2018Q2 us-gaap Restructuring Reserve
RestructuringReserve
7000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152331000 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165252000 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165300000 USD
CY2018Q2 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0 USD
CY2017Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
425000 USD
CY2018Q2 us-gaap Revenues
Revenues
0 USD
CY2018Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2018Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
41900000 USD
CY2018Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
25555556 shares
CY2018Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.80
us-gaap Severance Costs1
SeveranceCosts1
100000 USD
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
322000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
566000 USD
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
285000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
686000 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1738331 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
256111 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1643400 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2695796 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4027826 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.16
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3977226 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.67
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.53
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.95
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.82
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
55259 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
18034000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
64064000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24648000 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56421000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46105000 shares

Files In Submission

Name View Source Status
0001485003-18-000109-index-headers.html Edgar Link pending
0001485003-18-000109-index.html Edgar Link pending
0001485003-18-000109.txt Edgar Link pending
0001485003-18-000109-xbrl.zip Edgar Link pending
ebio-063018x10q.htm Edgar Link pending
ebio-063018x311.htm Edgar Link pending
ebio-063018x312.htm Edgar Link pending
ebio-063018x321.htm Edgar Link pending
ebio-20180630.xml Edgar Link completed
ebio-20180630.xsd Edgar Link pending
ebio-20180630_cal.xml Edgar Link unprocessable
ebio-20180630_def.xml Edgar Link unprocessable
ebio-20180630_lab.xml Edgar Link unprocessable
ebio-20180630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending